



Supplementary Figure S1. Correlation of the maximum ADE infectivity fold change at which the maximum viral entry with the antibody neutralization ID₅₀. **(A)** SARS-CoV-2 D614G neutralization titers of sera from convalescent individuals versus those after 3 doses of inactivated vaccinations. **(B)** Maximum ADE infectivity fold change of sera from convalescent individuals versus those after 3 doses of inactivated vaccinations. **(C)** Correlation of the maximum ADE infectivity fold change at which the maximum viral entry and the serum neutralization ID₅₀ for SARS-CoV-2 D614G virus. **(D)** Correlation of the maximum ADE infectivity fold change at which the maximum viral entry with mAbs neutralization IC₅₀ for SARS-CoV-2 D614G virus. A linear regression model was used for correlation analysis.



Supplementary Figure S2. No ADE of SARS-CoV-2 infection by mAbs was observed on THP-1 cells.



Supplementary Figure S3. Determination of the optimal NHS concentration in cell culture medium that is sufficient to eliminate LY-CoV1404 (1μg/ml) induced ADE activity on Raji cells.